Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.

A technology of myeloid leukemia, epituliprolactone, applied in the field of therapeutic agent for treating chronic myelogenous leukemia

Inactive Publication Date: 2016-01-27
CHO DANG PHARM
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the emergence of the T315I enzyme variant expressed by the mutated gene of BCR-ABL, such second generation therapeutics are no longer able to show sufficient efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.
  • Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.
  • Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] After the step of obtaining the lower alcohol aqueous mixture, the preparation method of the present application may need further 3 steps, which step includes: adding water to the lower alcohol aqueous mixture to obtain a low-concentration lower alcohol aqueous layer; adding dichloromethane to the alcoholic aqueous layer to separate the dichloromethane layer; and separating, concentrating and drying the material dissolved in the dichloromethane layer.

[0040] Liriodendron bark is collected from Liriodendron tulipifera located in Gangjin-gun, Jeollanam-do, Korea. After the collected bark of Liriodendron tulipifera was chopped and powdered, an extraction solvent was added in an amount 10-20 times that of the collected bark. Extraction was performed at room temperature to 50°C for 24-96 hours. Finally, the extract was obtained after concentration and drying under reduced pressure.

[0041] The present invention provides a method for extracting and purifying epilipolidol...

preparation example 1

[0054] (Preparation Example 1) Preparation of an extract from the bark of Liriodendron tulipifera using ethyl acetate solvent

[0055] 1. Solvent extraction step

[0056] 200 g of dried and chopped Liriodendron tulipifera (3-5 years old) bark was stirred and extracted with 2000 ml of ethyl acetate for 24 hours at room temperature. A preliminary extract was obtained after the extracted mixture was concentrated and filtered under reduced pressure. The resulting primary extract was further mixed and extracted with 500 ml butanol for 2-4 hours at room temperature. Then, the butanol soluble material was removed by separating and removing the butanol layer. After concentrating the remaining mixture, 12.54 g of crude extract was finally obtained.

[0057] 2. Purification steps

[0058] After 12.54 g of the obtained crude extract was dissolved in 200 ml of 70% ethanol, 200 ml of n-hexane was added to the crude extract mixture and stirred. After separating and removing the n-hexan...

preparation example 2

[0059] (Preparation example 2) Preparation of extract from the bark of Liriodendron tulipifera using ethyl acetate solvent

[0060] 1. Solvent extraction step

[0061] 200 g of dried and chopped Liriodendron tulipifera (3-5 years old) bark was stirred and extracted with 2000 ml of ethyl acetate for 72 hours at room temperature. A preliminary extract was obtained after the extracted mixture was concentrated and filtered under reduced pressure. The resulting primary extract was further mixed and extracted with 500 ml butanol for 2-4 hours at room temperature. Then, the butanol soluble material was removed by separating and removing the butanol layer. After concentrating the remaining mixture, 13.72 g of crude extract was finally obtained.

[0062] 2. Purification steps

[0063] After 13.72 g of the obtained crude extract was dissolved in 200 ml of 70% ethanol, 200 ml of n-hexane was added to the crude extract mixture and stirred. After separating and removing the n-hexane l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of Liriodendron tulipifera L., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a C1-C3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-Tulipinolide and costunolide.

Description

technical field [0001] The present invention relates to a process for the preparation of an extract from the bark of Liriodendron tulipifera containing epi-tulipinolide and costunolide for the treatment of chronic myelogenous leukemia. ) as the active ingredient. In addition, the present invention relates to a therapeutic agent for treating chronic myelogenous leukemia, the therapeutic agent comprising epituliprolactone and corylidene lactone extracted from the bark of Liriodendron tulipifera. Background technique [0002] Liriodendrontulipifera L., Yellow-poplar is a deciduous broad-leaved tree belonging to Magnoliaceae. The bark of Liriodendron tulipifera is known to contain alkaloids, sesquiterpenes and / or lignans. [0003] In addition, the extract of Liriodendron tulipifera contains sesquiterpene lactone compounds, including coynelide, tulipyl ester, epitulipdienolide, epi-tulipdienolide and / or γ-liriodenolide. [0004] Furthermore, parthenolide among these sesquiterp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/896A61P35/02
CPCA61K31/365A61K36/57A61K36/896A61K2236/00A61K2236/15A61K2236/333A61K2236/39A61P35/02A61P43/00
Inventor 金基运俞慧东金溶桓黄逸景金荣善周美贞姜秀珍
Owner CHO DANG PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com